curasan AG: REVOIS® All-in-One Dental Implant System Registered in the U.S.

--------------------------------------------------------------------------------
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
the content of this announcement.
--------------------------------------------------------------------------------

new product

Kleinostheim (euro adhoc) - curasan AG, a German leader in
regenerative medicine, has obtained FDA clearance for its REVOIS®
All-in-One dental implant system, permitting the sale of the system
in the U.S. This means that the system can be rolled out earlier than
originally planned - the rollout will take place at the ICOI World
Congress in San Francisco in late August 2007.

REVOIS® gives curasan direct access to the dental implant market, the
segment within dental surgery that generates the highest revenues and
earnings. Curasan Inc., the company´s U.S. sales organization, has
already been very successful in that country with its Cerasorb®
synthetic bone substitute and its Epi-Guide® resorbable membrane. The
excellent rapport with the target group, dental implantologists, and
with opinion leaders that the company has established with these
products are an excellent basis for marketing the REVOIS® All-in-One
dental implant system.

"This step represents another important milestone in the
implementation of our corporate strategy," said curasan´s CEO Hans
Dieter Rössler. "This strategy calls on us to organize our sales and
marketing activities with a clear focus on the dental market. Of
course, our R&D department will continue to develop new products for
use in orthopedics, for skin transplants and for other fields. These
will be marketed by way of license agreements and by cooperation with
multinational groups."

A Truly Useful Innovation: REVOIS® - the REVOlutionary Implant System
- is an intelligent modular system that achieves maximum precision
with a minimum number of parts, covering all implantological
requirements with only 120 components. This simplifies procurement,
allows the reduction of expensive inventory, and greatly enhances the
component selection process in actual clinical practice.

One pivotal element is the multi-functional precision abutment. It
fits all implant diameters and enables the user work with only one
prosthetic line.

The REVOIS All-in-One System was designed for clinicians who demand
highest quality and want to safely cover all implantological
requirements with a single system but who, nevertheless, value
simplicity of use and economical procedures as well as excellent
precision and esthetics. Implantologists, prosthodontists and dental
technicians can benefit from considerable savings in time and costs.

end of announcement euro adhoc 14.06.2007 09:26:04
--------------------------------------------------------------------------------

ots Originaltext: Curasan AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Kerstin Kornett
Vorstandsassistentin
Telefon: +49(0)6027 4686-431
E-Mail: kerstin.kornett@curasan.de

Branche: Biotechnology
ISIN: DE0005494538
WKN: 549453
Index: CDAX, Classic All Share, Prime All Share
Börsen: Frankfurter Wertpapierbörse / regulated dealing/prime
standard
Börse Berlin-Bremen / free trade
Hamburger Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Niedersächsische Börse zu Hannover / free trade
Bayerische Börse / free trade